1
In their well-designed prospective study, Gok et al 1 suggested that a low serum endocan level is a predictor of good coronary collateral development (CCD) in patients with stable coronary artery disease. Well-developed collateral arteries may limit myocardial infarct size and improve cardiovascular (CV) outcomes and survival. 2 Angiogenesis and inflammation may play a role in the pathophysiology of CCD. 3, 4 Endothelial cell-specific molecule 1 (endocan) is mainly secreted by vascular endothelial cells. 5 Endocan plays a role in endothelial dysfunction as a mediator of systemic inflammation and is associated with CV disease and CV mortality. 6, 7 The correlation of serum endocan levels with other inflammatory parameters (eg, white blood cell and neutrophil counts) reported by Gok et al 1 supports its role in systemic inflammation. Correlation analysis also indicated that endocan levels showed a significant and positive correlation with high-sensitivity C-reactive protein (hsCRP; P < .001).
1 However, many other inflammatory and angiogenic factors may play a role in CCD, such as vascular cell adhesion molecule-1 (VCAM-1), erythropoietin, nitric oxide, YKL-40 (an indicator of inflammation), serum vitamin D, and monocyte to high-density lipoprotein cholesterol ratio, which were not measured in the study by Gok et al. 8, 9 In addition, unlike the study by Gok et al, 1 Emet et al 10 demonstrated that a higher endocan level was related to better CCD. Furthermore, there was a strong correlation between serum VCAM-1 (an angiogenetic indicator) levels and serum endocan levels (r ¼ .73, P < .001). Also, they indicated a negative correlation between serum endocan levels and hsCRP levels (r ¼ À.35, P ¼ .001). 10 According to these results, 1,10 endocan has a negative effect on CCD due to causing both inflammation and endothelial dysfunction 1 but may also improve CCD due to its potential angiogenic feature such as VCAM-1. 10 Probably, the same stimuli such as myocardial ischemia, hypoxia, and inflammatory process may increase both endocan and VCAM-1 levels. 2, 10 Since there are many conflicting results in these 2 recent studies on CCD, 1,10 the findings of Gok et al 1 must be interpreted in the light of several confounding factors before making a definite decision concerning the role of endocan in CCD.
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